Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–158 of 158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: IV diphenhydramine Clear all

Conditions: Renal Cell Carcinoma
Interventions: Sorafenib, temsirolimus (Torisel); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 19 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 25
States / cities: Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more

Conditions: Nausea and Vomiting Post-foregut Surgery
Interventions: Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge; Device · Drug
Lead sponsor: Kyle A Perry; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Nonmyeloablative allogeneic stem cell transplant; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 86
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more

Conditions: IgG4 Related Disease, IgG4-RD
Interventions: elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: TPI 287, Dexamethasone, Benadryl, Ranitidine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Palbociclib; Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastric Adenocarcinoma, Carcinomatosis
Interventions: Paclitaxel, Dexamethasone, Diphenhydramine, Famotidine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hairy Cell Leukemia
Interventions: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Surgery, Pain
Interventions: .9 normal saline, 25 mg diphenhydramine IV, 50 mg diphenhydramine IV; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
Interventions: paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 14 Years and older · Male only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 77
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more

Conditions: Hairy Cell Leukemia
Interventions: Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post-Traumatic Headache
Interventions: Metoclopramide, Diphenhydramine, Normal saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

TPI 287 in Breast Cancer Metastatic to the Brain

Tazemetostat and Palbociclib With CPX-351for R/R AML

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Metoclopramide for Post Traumatic Headache